Technical Analysis for PSTX - Poseida Therapeutics, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Calm After Storm | Range Contraction | 0.00% | |
NR7 | Range Contraction | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Down 3 Days in a Row | Weakness | 0.00% | |
50 DMA Resistance | Bearish | -4.97% | |
Calm After Storm | Range Contraction | -4.97% | |
Wide Bands | Range Expansion | -4.97% | |
Fell Below 50 DMA | Bearish | -5.56% | |
MACD Bearish Centerline Cross | Bearish | -5.56% | |
Calm After Storm | Range Contraction | -5.56% |
Alert | Time |
---|---|
Possible NR7 | about 11 hours ago |
Up 1% | about 13 hours ago |
Down 5% | about 14 hours ago |
Down 3% | about 15 hours ago |
Fell Below Previous Day's Low | about 15 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 03/07/2024
Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of non-viral gene engineering technologies for the treatment of hematological malignancies and solid tumors. Its products pipeline include autologous and allogeneic chimeric antigen receptor T cell, or CAR-T. The company was founded by Eric M. Ostertag in 2014 and is headquartered in San Diego, CA.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Life Sciences Clinical Medicine Solid Tumors Immune System Cancer Treatment Lymphoma Leukemia Chimeric Antigen Receptor T Cell Hematological Malignancies Chimeric Antigen Receptor Cellectis
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Life Sciences Clinical Medicine Solid Tumors Immune System Cancer Treatment Lymphoma Leukemia Chimeric Antigen Receptor T Cell Hematological Malignancies Chimeric Antigen Receptor Cellectis
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 4.27 |
52 Week Low | 1.54 |
Average Volume | 777,143 |
200-Day Moving Average | 2.60 |
50-Day Moving Average | 3.39 |
20-Day Moving Average | 3.51 |
10-Day Moving Average | 3.41 |
Average True Range | 0.36 |
RSI (14) | 42.86 |
ADX | 24.32 |
+DI | 15.44 |
-DI | 25.02 |
Chandelier Exit (Long, 3 ATRs) | 3.20 |
Chandelier Exit (Short, 3 ATRs) | 3.93 |
Upper Bollinger Bands | 4.10 |
Lower Bollinger Band | 2.92 |
Percent B (%b) | 0.12 |
BandWidth | 33.60 |
MACD Line | -0.06 |
MACD Signal Line | 0.02 |
MACD Histogram | -0.0767 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 3.40 | ||||
Resistance 3 (R3) | 3.43 | 3.35 | 3.34 | ||
Resistance 2 (R2) | 3.35 | 3.27 | 3.34 | 3.32 | |
Resistance 1 (R1) | 3.21 | 3.21 | 3.17 | 3.17 | 3.30 |
Pivot Point | 3.13 | 3.13 | 3.11 | 3.11 | 3.13 |
Support 1 (S1) | 2.98 | 3.04 | 2.94 | 2.95 | 2.82 |
Support 2 (S2) | 2.90 | 2.99 | 2.89 | 2.80 | |
Support 3 (S3) | 2.76 | 2.90 | 2.78 | ||
Support 4 (S4) | 2.72 |